Last reviewed · How we verify
Adipose Mesenchymal stem cells
Adipose-derived mesenchymal stem cells promote tissue repair and regeneration through immunomodulation, anti-inflammatory signaling, and differentiation into functional cell types.
Adipose-derived mesenchymal stem cells promote tissue repair and regeneration through immunomodulation, anti-inflammatory signaling, and differentiation into functional cell types. Used for Tissue regeneration and repair (specific indication under investigation in Phase 3 trial not publicly detailed).
At a glance
| Generic name | Adipose Mesenchymal stem cells |
|---|---|
| Sponsor | Universidad Catolica Santiago de Guayaquil |
| Drug class | Cell therapy |
| Modality | Biologic |
| Therapeutic area | Regenerative Medicine |
| Phase | Phase 3 |
Mechanism of action
Adipose mesenchymal stem cells (ASCs) are multipotent cells harvested from adipose tissue that exert therapeutic effects via paracrine secretion of anti-inflammatory cytokines and growth factors, modulation of immune responses, and direct differentiation into osteogenic, chondrogenic, and other lineages. These cells reduce inflammatory markers, promote angiogenesis, and support tissue regeneration in damaged or degenerative tissues.
Approved indications
- Tissue regeneration and repair (specific indication under investigation in Phase 3 trial not publicly detailed)
Common side effects
- Injection site reactions
- Fever
- Infection risk
Key clinical trials
- Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments (PHASE2)
- Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells (PHASE1)
- Autologous SVF Therapy for Type 2 Diabetes (NA)
- Stem Cells for Erectile Dysfunction Post RALP (PHASE1, PHASE2)
- Safety and Efficacy of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars (PHASE1, PHASE2)
- "An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."
- A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle (PHASE3)
- Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |